Gastric Motility Disorder Drugs Market is expected to reach US$ 90.41 billion by 2033 | Emerging key players - Processa Pharmaceuticals, Inc., Vanda Pharmaceuticals Inc., Renexxion Ireland Limited.

Market Size and Growth:

The Global Gastric Motility Disorder Drugs Market size reached US$ 54.7 billion in 2024 and is expected to reach US$ 90.41 billion by 2033, growing at a CAGR of 5.0% during the forecast period 2025-2033.

The Gastric Motility Disorder Drugs Market report, published by DataM Intelligence, provides in-depth insights and analysis on key market trends, growth opportunities, and emerging challenges. Committed to delivering actionable intelligence, DataM Intelligence empowers businesses to make informed decisions and stay ahead of the competition. Through a combination of qualitative and quantitative research methods, it offers comprehensive reports that help clients navigate complex market landscapes, drive strategic growth, and seize new opportunities in an ever-evolving global market.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://datamintelligence.com/download-sample/gastric-motility-disorder-drugs-market?sz

The Gastric Motility Disorder Drugs Market refers to the global industry focused on developing, manufacturing, and distributing medications that improve or regulate stomach motility. These drugs treat conditions such as gastroparesis, functional dyspepsia, and chronic nausea by enhancing gastric emptying, reducing symptoms, and improving digestive function across hospital, retail, and online pharmacy channels, serving adult and pediatric patients worldwide effectively safely.

Recent Key Developments of United States:

✅ December 2025: The FDA approved Vanda Pharmaceuticals' tradipitant (NEREUS) for motion sickness prevention, advancing its profile amid continued pursuit for gastroparesis treatment.

✅ November 2025: Aclipse Therapeutics announced a collaboration with Mayo Clinic for Phase 2 development of M107, a potential disease-modifying drug for gastroparesis, with enrollment set to begin in Q1 2026.

✅ October 2025: Vanda Pharmaceuticals and the FDA agreed to a collaborative framework pausing disputes over tradipitant for gastroparesis until January 2026, supporting ongoing regulatory review.

Recent Key Developments of Europe:

✅ December 2025: Europe's gastric motility disorder drug market showed opportunistic growth potential due to aging populations and demand for evidence-based therapies, as highlighted in recent analyses.

✅ November 2025: Dr. Falk Pharma and Renexxion Ireland progressed Phase IIb trials of naronapride for gastroparesis across Europe, building on prior gastric emptying data.

✅ October 2025: The gastroparesis market saw emphasis on novel therapies like PCS12852 and naronapride, with Europe benefiting from regulatory incentives and multi-center studies in countries like Germany and France.

List of the Key Players in the Gastric Motility Disorder Drugs Market:

Pfizer Inc.
Eisai Co., Ltd.
Mallinckrodt
Salvus Pharma
Atmo Biosciences
AdvaCare Pharma
Avenacy
VAIKUNTH CHEMICALS PVT. LTD.
Healthy Inc
Bhumi Pharmaceuticals

Emerging Market Players:

Processa Pharmaceuticals, Inc.
Vanda Pharmaceuticals Inc.
Renexxion Ireland Limited
Aclipse Therapeutics

Speak to Our Analyst and Get Customization in the report as per your requirements: https://datamintelligence.com/customize/gastric-motility-disorder-drugs-market?sz

This Report Covers:

✔ Go-to-market Strategy.

✔ Neutral perspective on the market performance.

✔Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.

✔Customized regional/country reports as per request and country level analysis.

✔ Potential & niche segments and regions exhibiting promising growth covered.

✔ Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).

Segments Covered in the Gastric Motility Disorder Drugs Market:

By Drug Type: Parasympathomimetics, Prokinetic Agents, Opioid Antagonists, Antidiarrheals, Anti-Emetic Drugs, Antibiotics, Others.

By Disorder Type: Achalasia, Esophageal spasms, Heartburn, or Gastroesophageal Reflux Disease (GERD), Gastroparesis, Irritable Bowel Syndrome (IBS), Fecal incontinence, Intestinal Pseudo-obstruction, Others.

By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies.

Regional Analysis:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Looking For Full Report? Get it Here: https://www.datamintelligence.com/buy-now-page?report=gastric-motility-disorder-drugs-market

Chapter Outline

⏩ Market Overview: It contains five chapters, as well as information about the research scope, major manufacturers covered, market segments, Gastric Motility Disorder Drugs market segments, study objectives, and years considered.

⏩ Market Landscape: The competition in the Global Gastric Motility Disorder Drugs Market is evaluated here in terms of value, turnover, revenues, and market share by organization, as well as market rate, competitive landscape, and recent developments, transaction, growth, sale, and market shares of top companies.

⏩ Companies Profiles: The Global Gastric Motility Disorder Drugs market's leading players are studied based on sales, main products, gross profit margin, revenue, price, and growth production.

⏩ Market Outlook by Region: The report goes through gross margin, sales, income, supply, market share, CAGR, and market size by region in this segment. North America, Europe, Asia Pacific, Middle East & Africa, and South America are among the regions and countries studied in depth in this study.

⏩ Market Segments: It contains the deep research study which interprets how different end-user/application/type segments contribute to the Gastric Motility Disorder Drugs Market.

⏩ Market Forecast: Production Side: In this part of the report, the authors have focused on production and production value forecast, key producers forecast, and production and production value forecast by type.

⏩ Research Findings: This section of the report showcases the findings and analysis of the report.

⏩ Conclusion: This portion of the report is the last section of the report where the conclusion of the research study is provided.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

People Also Ask:

◆ How big is the Gastric Motility Disorder Drugs Market in 2025?
◆ What is the projected growth rate of the Gastric Motility Disorder Drugs Market through 2033?
◆ Who are the key players in the Gastric Motility Disorder Drugs Market?
◆ Which region is expected to dominate the industry during the forecast period?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.